糖组检测在肝脏疾病诊疗中的应用现状与未来展望

王蕾; 李维泉; 陈力; 陈萃英

糖组检测在肝脏疾病诊疗中的应用现状与未来展望

王蕾¹,
李维泉¹,
陈力²,
陈萃英^1, ,

1. 先思达生物科技有限公司, 江苏南京 211800;
2. 复旦大学上海医学院教育部/卫生部医学分子病毒学重点实验室, 上海 200032

基金项目:

“十二五”重大新药创制（No.2014ZX09101046-004)，泰州市113高层次创新人才项目

详细信息

作者简介:
王蕾: 陈萃英：先思达生物科技有限公司董事长，比利时根特大学（Ghent University）生物工程博士。陈博士于2004年任职根特大学及弗兰德斯生物技术研究所（VIB）分子生物医学实验室研究组负责人。她领导的研究组开创了后基因组学——糖组学的应用理念，凭借对糖组这一新型标志物的应用发现与检测技术的重大创新，为糖组学从理论研究到临床应用的迈进奠定了坚实的基础、提供了先进的技术、拓展了广阔的空间。据此成果，陈博士荣获比利时FFMI-肿瘤标志物最新发明奖、欧洲华人十大科技创业创新人物奖，在SCI国际学术期刊上发表50多篇独立研究学术论文，在国内外申请专利12项、获得专利授权9项。2012年起，陈萃英博士创建了先思达（南京）生物科技有限公司，建立起国际上首个基于糖组学检测技术的测序平台，针对十几项重大疾病种类开发检测、诊断产品。2018年先思达首个肝癌检测诊断产品G-Test寡糖链检测试剂盒被认定为国家创新产品。

通讯作者:
陈萃英, 博士

中图分类号: R575
计量
- 文章访问数: 225
- HTML全文浏览量: 10
- PDF下载量: 36
出版历程
- 收稿日期: 2021-09-14

Application Status and Future Prospect of Glycome Test in Liver Disease Diagnosis and Treatment

1. Sysdiagno Biomedtech Co.,Ltd.,Nanjing 211800, China;
2. Ministry of Education/National Health Commission Key Laboratory of Medical Molecular Virology, Fudan University Shanghai Medical College, Shanghai 200032, China

More Information

Corresponding author:
CHEN Cuiying, 博士

摘要

摘要: 糖组泛指在特定的时间、空间和环境下细胞和组织产生的所有糖链的集合。蛋白上糖链的合成受到了基因的严格调控，且很少受环境影响。并且，个体水平上血清中糖组非常稳定。研究人员在肝病研究中发现，岩藻糖、多分支、平分N-乙酰葡糖胺和唾液酸等糖型均发生了显著的变化。综述了糖组检测在肝纤维化、肝硬化、肝癌的诊疗及肝移植中的应用进展。
- 糖组 /
- 糖基化 /
- 糖链 /
- 糖蛋白 /
- 肝病 /
- 肝癌 /
- 血清
Abstract: Glycome refers to the collection of glycans produced by cell and tissue under defined situations of time, location and environment. Synthesis of glycan on protein is strictly regulated by genes while rarely affected by the environment. Besides, Serum glycome is very stable at the individual level. In the studies of liver diseases, researchers have found significant changes in fucosylation, brancing, bisecting N-acetylglucosamine and sialic acid of glycans. This article reviews the advances in the application of glycome test in the diagnosis and treatment of liver fibrosis, liver cirrhosis, liver cancer and liver transplantation.
- glycome /
- glycosylation /
- glycan /
- glycoprotein /
- liver disease /
- hepatocellular carcinoma /
- serum

HTML全文

参考文献(53)

[1]	Moremen K W, Tiemeyer M, Nairn A V. Vertebrate protein glycosylation:diversity, synthesis and function[J].Nat Rev Mol Cell Biol, 2012, 13(7):448-462.
[2]	Flynn R A, Pedram K, Malaker S A, et al. Small RNAs are modified with N-glycans and displayed on the surface of living cells[J].Cell, 2021, 184(12):3109-3124 e3122.DOI: 10.1016/j.cell.2021.04.023.
[3]	Haltiwanger R S, Lowe J B. Role of glycosylation in development[J].Annu Rev Biochem, 2004, 73:491-537.
[4]	Varki A, Cummings R D, Esko J D, et al. Essentials of Glycobiology[M]. New York:Cold Spring Harbor Laboratory Press, 2017:651.
[5]	Hart G W, Copeland R J. Glycomics hits the big time[J].Cell, 2010, 143(5):672-676.
[6]	Mehta A, Herrera H, Block T. Glycosylation and liver cancer[J].Adv Cancer Res, 2015, 126:257-279.
[7]	Liebman H A, Furie B C, Tong M J, et al. Des-gammacarboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma[J].N Engl J Med, 1984, 310(22):1427-1431.
[8]	Feng H, Li B, Li Z, et al. PIVKA-Ⅱ serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma[J].BMC Cancer, 2021, 21(1):401.DOI: 10.1186/s12885-021-08138-3.
[9]	Xu R H, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J].Nat Mater, 2017, 16(11):1155-1161.
[10]	Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J].J Clin Oncol, 2011, 29(36):4781-4788.
[11]	Clerc F, Reiding K R, Jansen B C, et al. Human plasma proteinN-glycosylation[J].Glycoconj J, 2016, 33(3):309-343.
[12]	Schachter H, Freeze H H. Glycosylation diseases:quo vadis?[J].Biochim Biophys Acta, 2009, 1792(9):925-930.
[13]	Jaeken J. Congenital disorders of glycosylation[J].Ann N Y Acad Sci, 2010, 1214:190-198.
[14]	Ohtsubo K, Marth J D. Glycosylation in cellular mechanisms of health and disease[J].Cell, 2006, 126(5):855-867.
[15]	Pinho S S, Reis C A. Glycosylation in cancer:mechanisms and clinical implications[J].Nat Rev Cancer, 2015, 15(9):540-555.
[16]	Knezevic A, Polasek O, Gornik O, et al. Variability, heritability and environmental determinants of human plasma N-glycome[J].J Proteome Res, 2009, 8(2):694-701.
[17]	Gornik O, Wagner J, Pucic M, et al. Stability of N-glycan profiles in human plasma[J].Glycobiology, 2009, 19(12):1547-1553.
[18]	The Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma[J].Cell, 2017, 169(7):1327-1341.
[19]	Kamada Y, Akita M, Takeda Y, et al. Serum fucosylated haptoglobin as a novel diagnostic biomarker for predicting hepatocyte ballooning and nonalcoholic steatohepatitis[J].PLoS One, 2013, 8(6):e66328.DOI: 10.1371/journal.pone.0066328.
[20]	Comunale M A, Lowman M, Long R E, et al. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma[J].J Proteome Res, 2006, 5(2):308-315.
[21]	Sanda M, Zhang L, Edwards N J, et al. Site-specific analysis of changes in the glycosylation of proteins in liver cirrhosis using data-independent workflow with soft fragmentation[J].Anal Bioanal Chem, 2017, 409(2):619-627.
[22]	Nie H, Liu X, Zhang Y, et al. Specific N-glycans of hepatocellular carcinoma cell surface and the abnormal increase of core-alpha-1, 6-fucosylated triantennary glycan viaN-acetylglucosaminyltransferases-IVa regulation[J].Sci Rep, 2015, 5:16007.DOI: 10.1038/srep16007.
[23]	Shiraki K, Takase K, Tameda Y, et al. A clinical study of lectinreactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients[J].Hepatology, 1995, 22(3):802-807.
[24]	Wu C S, Lee T Y, Chou R H, et al. Development of a highly sensitive glycan microarray for quantifying AFP-L3 for early prediction of hepatitis B virus-related hepatocellular carcinoma[J].PLoS One, 2014, 9(6):e99959.DOI: 10.1371/journal.pone.0099959.
[25]	West C A, Wang M, Herrera H, et al. N-linked glycan branching and fucosylation are increased directly in hcc tissue as determined through in situ glycan imaging[J].J Proteome Res, 2018, 17(10):3454-3462.
[26]	Ito Y, Miyoshi E, Sakon M, et al. Elevated expression of UDP-N-acetylglucosamine:alphamannoside beta1, 6N-acetylglucosaminyltransferase is an early event in hepatocarcinogenesis[J].Int J Cancer, 2001, 91(5):631-637.
[27]	Hachulla E, Laine A, Hedouin V, et al. Variations in the glycoforms of serum alpha 1-antichymotrypsin in liver diseases and after liver transplantation[J].Clin Sci, 1992, 82(4):439-446.
[28]	Mondal G, Chatterjee U, Chawla Y K, et al. Alterations of glycan branching and differential expression of sialic acid on alpha fetoprotein among hepatitis patients[J].Glycoconj J, 2011, 28(1):1-9.
[29]	Mehta A, Norton P, Liang H, et al. Increased levels of tetraantennary N-linked glycan but not core fucosylation are associated with hepatocellular carcinoma tissue[J].Cancer Epidemiol Biomarkers Prev, 2012, 21(6):925-933.
[30]	Mori S, Aoyagi Y, Yanagi M, et al. Serum N-acetylglucosaminyltransferase Ⅲ activities in hepatocellular carcinoma[J].J Gastroenterol Hepatol, 1998, 13(6):610-619.
[31]	Callewaert N, Van Vlierberghe H, Van Hecke A, et al.Noninvasive diagnosis of liver cirrhosis using DNA sequencerbased total serum protein glycomics[J].Nat Med, 2004, 10(4):429-434.
[32]	Liu X E, Desmyter L, Gao C F, et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus[J].Hepatology, 2007, 46(5):1426-1435.
[33]	Miyoshi E, Nishikawa A, Ihara Y, et al. N-acetylglucosaminyltransferase Ⅲ and V messenger RNA levels in LEC rats during hepatocarcinogenesis[J].Cancer Res, 1993, 53(17):3899-3902.
[34]	Nishikawa A, Gu J, Fujii S, et al. Determination of N-acetylglucosaminyltransferases Ⅲ, IV and V in normal and hepatoma tissues of rats[J].Biochim Biophys Acta, 1990, 1035(3):313-318.
[35]	Koenderman A H, Koppen P L, Koeleman C A, et al.N-acetylglucosaminyltransferase Ⅲ, IV and V activities in Novikoff ascites tumour cells, mouse lymphoma cells and hen oviduct. Application of a sensitive and specific assay by use of high-performance liquid chromatography[J].Eur J Biochem, 1989, 181(3):651-655.
[36]	Dennis J W, Laferte S, Waghorne C, et al. Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis[J].Science, 1987, 236(4801):582-585.
[37]	Shim J K, Lee Y C, Chung T H, et al. Elevated expression of bisecting N-acetylglucosaminyltransferase-Ⅲ gene in a human fetal hepatocyte cell line by hepatitis B virus[J].J Gastroenterol Hepatol, 2004, 19(12):1374-1387.
[38]	Dall'Olio F, Chiricolo M, D'Errico A, et al. Expression of betagalactoside alpha2, 6 sialyltransferase and of alpha2, 6-sialylated glycoconjugates in normal human liver, hepatocarcinoma, and cirrhosis[J].Glycobiology, 2004, 14(1):39-49.
[39]	Sun C, Chen P, Chen Q, et al. Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients[J].Acta Biochim Biophys Sin (Shanghai), 2012, 44(9):765-773.
[40]	Kam R K, Poon T C, Chan H L, et al. High-throughput quantitative profiling of serum N-glycome by MALDI-TOF mass spectrometry and N-glycomic fingerprint of liver fibrosis[J].Clin Chem, 2007, 53(7):1254-1263.
[41]	Gui H L, Gao C F, Wang H, et al. Altered serum N-glycomics in chronic hepatitis B patients[J].Liver Int, 2010, 30(2):259-267.
[42]	Qu Y, Gao C F, Zhou K, et al. Serum N-glycomic markers in combination with panels improves the diagnosis of chronic hepatitis B[J].Ann Hepatol, 2012, 11(2):202-212.
[43]	Cao X, Shang Q H, Chi X L, et al. Serum N-glycan markers for diagnosing liver fibrosis induced by hepatitis B virus[J].World J Gastroenterol, 2020, 26(10):1067-1079.
[44]	Comunale M A, Wang M, Anbarasan N, et al. Total serum glycan analysis is superior to lectin-FLISA for the early detection of hepatocellular carcinoma[J].Proteomics Clin Appl, 2013, 7(9/10):690-700.
[45]	Cong M, Ou X, Huang J, et al. A predictive model using N-glycan biosignatures for clinical diagnosis of early hepatocellular carcinoma related to hepatitis B virus[J].OMICS, 2020, 24(7):415-423.
[46]	Verhelst X, Geerts A, Jochmans I, et al. Glycome patterns of perfusate in livers before transplantation associate with primary nonfunction[J].Gastroenterology, 2018, 154(5):1361-1368.
[47]	Zielinska D F, Gnad F, Wisniewski J R, et al. Precision mapping of an in vivo N-glycoproteome reveals rigid topological and sequence constraints[J].Cell, 2010, 141(5):897-907.
[48]	Wang H, Wong C H, Chin A, et al. Integrated mass spectrometrybased analysis of plasma glycoproteins and their glycan modifications[J].Nat Protoc, 2011, 6(3):253-269.
[49]	Briggs M T, Condina M R, Klingler-Hoffmann M, et al.Translating N-glycan analytical applications into clinical strategies for ovarian cancer[J].Proteomics Clin Appl, 2019, 13(3):e1800099.DOI: 10.1002/prca.201800099.
[50]	Bladergroen M R, Reiding K R, Hipgrave Ederveen A L, et al. Automation of high-throughput mass spectrometry-based plasma N-glycome analysis with linkage-specific sialic acid esterification[J].J Proteome Res, 2015, 14(9):4080-4086.
[51]	Laroy W, Contreras R, Callewaert N. Glycome mapping on DNA sequencing equipment[J].Nat Protoc, 2006, 1(1):397-405.
[52]	Kuno A, Ikehara Y, Tanaka Y, et al. A serum "sweet-doughnut"protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis[J].Sci Rep, 2013, 3:1065.DOI: https://doi.org/10.1038/srep01065.
[53]	中国肝炎防治基金会编辑委员会. 慢性乙型肝炎病毒感染者肝细胞癌筛查和监测专家指导意见[J]. 中华肝脏病杂志, 2021, 29(10):939-947.

施引文献(2)

期刊类型引用(2)

1.	任轲，田李均，黄晓英，韩旭东，章颖. 血清神经元特异性烯醇化酶等指标预测肝硬化合并显性肝性脑病患者预后的价值. 实用临床医药杂志. 2024(17): 35-40 . 百度学术
2.	孙桂芹，陈妍雯，张绍兴，刘瑞杰，张瑜芯，芦鑫荣，童永亮，陈力，陈萃英. 基于糖谱的体外检测和诊断的临床应用研究进展. 药学进展. 2023(06): 424-432 . 本站查看